Sugi Predict

Sugi Predict / Compounds / SCHEMBL10109877

SCHEMBL10109877

SCHEMBL10109877

O=C1CN(C(=O)c2cc(-c3cccc(Cl)c3)c(-c3cccc(Cl)c3)s2)CN1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 1/20 0.39
▸ RAB9A P51151 6/20 0.36
▸ NPC1 O15118 5/20 0.36
▸ TP53 P04637 2/20 0.35
▸ THRB P10828 1/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ HPGD P15428 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ MAPK10 P53779 1/20 0.35
▸ GAA P10253 2/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34
▸ SLC6A7 Q99884 1/20 0.34
▸ SLC9A1 P19634 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ TDP2 O95551 2/20 0.34
▸ PARP10 Q53GL7 1/20 0.34
▸ PARP11 Q9NR21 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL421601 0.92 MAPK14 (0.40) MAPK14RAB9ANPC1SMN1; SMN2GAA
SCHEMBL14748311 0.91 MAPK14 (0.34) MAPK14RAB9ANPC1TP53THRB
SCHEMBL424682 0.91 PTGDR2 (0.38) MAPK14TP53MEN1KMT2ASLC6A7
SCHEMBL422736 0.91 MAPK14 (0.41) MAPK14RAB9ANPC1TP53THRB
SCHEMBL421762 0.89 SLC5A1 (0.40) MAPK14SLC6A7
SCHEMBL423833 0.88 MAPK14 (0.37) MAPK14HPGDGAAALDH1A1
SCHEMBL424176 0.88 MAPK14 (0.37) MAPK14HPGDGAAALDH1A1
SCHEMBL423778 0.88 RAB9A (0.38) RAB9ANPC1TP53THRBSMN1; SMN2
SCHEMBL426734 0.88 HCRTR1 (0.39) RAB9ANPC1TP53THRBSMN1; SMN2
SCHEMBL14748327 0.88 TSHR (0.46) NPC1TP53SMN1; SMN2HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 — — US disclosed
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 — — US disclosed
EP-2376482-B1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2013-03-06 — — EP disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 — — US disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 — — US disclosed
WO-2010075962-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2010-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF TPMT, MAVS, EIF2AK2 MAPK14 2294/4885RAB9A 2719/4885NPC1 435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.